

ASX RELEASE

Volpara Launches **VolparaEnterprise™ 2.0** Software

Wellington, NZ, 5th April 2017: Volpara Health Technologies ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, is pleased to announce the commercial launch of **VolparaEnterprise™ 2.0** software, an enhanced version of VHT's cloud-based breast imaging analytics platform, as foreshadowed by the prospectus in November 2016.

VolparaEnterprise™ 2.0 software delivers real-time quality assurance and performance monitoring through dynamic, interactive dashboards that update over 100 key indicators and quality metrics with every mammography or tomosynthesis exam. With role-based access to such data, employees of large and small practices alike can perform rapid quality control checks that optimise the productivity and efficiency of imaging resources. In turn, this helps decrease costs through the reduction of retakes, increase employee effectiveness and enhance patient experience.

Among the updates to **VolparaEnterprise™ 2.0** software are a wholly redesigned user interface and a new technologist dashboard which enables breast imaging facilities' technologists to track their own performance, setting the stage for improved compression and positioning of women. Based on Microsoft's robust Azure data technology, **VolparaEnterprise™ 2.0** software is fully integrated with **VolparaDensity™** software, the original 3D density solution.

The launch of **VolparaEnterprise™ 2.0** software is very timely as the FDA has stepped up its compliance standards through its update to the Mammography Quality Standards Act (MQSA) inspections, the Enhancing Quality Using the Inspection Program (EQUIP) initiative.

As the only solution currently available that provides a comprehensive assessment of image quality on every screening mammogram, **VolparaEnterprise™ 2.0** software is poised to help US breast imaging centres meet these new quality standards.

Already underway is Boca Raton Regional Hospital in Florida, whose Shakira Sarquis-Kolber, Director of Women's Imaging, said: "We already knew that VolparaEnterprise is an invaluable tool for understanding the quality of breast imaging services we deliver. Most recently, **VolparaEnterprise™ 2.0** software showed that our radiologists are not referring all the patients they could after we discovered that the average age of our dense patients is considerably lower than our referrals average. Therefore, we have an opportunity to provide more women with the adjunctive imaging they need."

To date Volpara has signed 14 breast imaging centres to **VolparaEnterprise™** software, with five joining in the last month alone. These sites are running a mix of the 2.0 and 1.0 versions, with those on the latter in the process of transitioning to the updated software.

Dr Ralph Highnam, CEO of Volpara Health Technologies, said the release of **VolparaEnterprise™ 2.0** software represents a turning point in the application of digital health solutions to issues in clinical performance.

“The goal is always better patient outcomes, and **VolparaEnterprise™** 2.0 software, by providing a wide array of easily accessible quality control features and data, helps breast imaging centres achieve them,” he said.

“Furthermore, by quantifying common staff errors, it enables managers to focus on improving human performance. Over time this will ensure more consistent and appropriate breast positioning and compression, and thus provide centres with the image quality needed for compliance with the more stringent requirements of the EQUIP initiative, as well as similar standards around the world.”

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 35 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722